Moreover, tumor-specific and transporter-targeted sugar conjugates would possess more favorable toxicity profiles and enhanced tumor selectivity and antitumor potency due to GLUT and OCT-mediated drug uptake, which is desired in antitumor agents for targeted therapy drugs. The gene discussed is SLC2A1; the disease is neoplasm.